Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Pasello

Showing results (131-140 of 167) with videos related to

Pageof 17
Sort By:
Cancers|October 17, 2020
Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES StudyMaria Pagano, Luca Giovanni Ceresoli, Paolo Andrea Zucali, et al.
Future Oncology (London, England)|May 14, 2021
Real-world data on treatment outcomes in <i>EGFR</i>-mutant non-small-cell lung cancer patients receiving osimertinib in second or further linesAlessandro Dal Maso, Martina Lorenzi, Alessandra Ferro, et al.
The Oncologist|November 17, 2025
Machine learning identifies a distinct microbiota signature in immune checkpoint inhibitor colitis compared with inflammatory bowel diseaseBrigida Barberio, Ilaria Patuzzi, Luisa Bertin, et al.
Lung Cancer (Amsterdam, Netherlands)|December 19, 2024
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016Francesco Gelsomino, Luca Boni, Marcello Tiseo, et al.
The Journal of Liquid Biopsy|March 3, 2025
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centersMichela Verzè, Andrea Boscolo Bragadin, Roberta Minari, et al.
Translational Lung Cancer Research|November 19, 2020
<i>SMO</i> mutations confer poor prognosis in malignant pleural mesotheliomaDiego Signorelli, Claudia Proto, Laura Botta, et al.
Journal of Translational Medicine|March 5, 2024
Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patientsGiulia Pasello, Aline S C Fabricio, Paola Del Bianco, et al.
The Oncologist|April 16, 2022
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving NivolumabGiulia Pasello, Martina Lorenzi, Lorenzo Calvetti, et al.
Clinical Lung Cancer|June 17, 2026
CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural MesotheliomaGiulia Pasello, Daniela Scattolin, Eleonora Faccioli, et al.
Cancers|January 25, 2025
The Rare Entity of Basaloid Thymic Carcinoma: A Multicentric Retrospective Analysis from the Italian Collaborative Group for ThYmic MalignanciEs (TYME)Chiara Catania, Sara Manglaviti, Paolo Zucali, et al.
Pageof 17

Showing results (131-140 of 167) with videos related to

Sort By:
Pageof 17
Cancers|October 17, 2020
Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES StudyMaria Pagano, Luca Giovanni Ceresoli, Paolo Andrea Zucali, et al.
Future Oncology (London, England)|May 14, 2021
Real-world data on treatment outcomes in <i>EGFR</i>-mutant non-small-cell lung cancer patients receiving osimertinib in second or further linesAlessandro Dal Maso, Martina Lorenzi, Alessandra Ferro, et al.
The Oncologist|November 17, 2025
Machine learning identifies a distinct microbiota signature in immune checkpoint inhibitor colitis compared with inflammatory bowel diseaseBrigida Barberio, Ilaria Patuzzi, Luisa Bertin, et al.
Lung Cancer (Amsterdam, Netherlands)|December 19, 2024
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016Francesco Gelsomino, Luca Boni, Marcello Tiseo, et al.
The Journal of Liquid Biopsy|March 3, 2025
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centersMichela Verzè, Andrea Boscolo Bragadin, Roberta Minari, et al.
Translational Lung Cancer Research|November 19, 2020
<i>SMO</i> mutations confer poor prognosis in malignant pleural mesotheliomaDiego Signorelli, Claudia Proto, Laura Botta, et al.
Journal of Translational Medicine|March 5, 2024
Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patientsGiulia Pasello, Aline S C Fabricio, Paola Del Bianco, et al.
The Oncologist|April 16, 2022
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving NivolumabGiulia Pasello, Martina Lorenzi, Lorenzo Calvetti, et al.
Clinical Lung Cancer|June 17, 2026
CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural MesotheliomaGiulia Pasello, Daniela Scattolin, Eleonora Faccioli, et al.
Cancers|January 25, 2025
The Rare Entity of Basaloid Thymic Carcinoma: A Multicentric Retrospective Analysis from the Italian Collaborative Group for ThYmic MalignanciEs (TYME)Chiara Catania, Sara Manglaviti, Paolo Zucali, et al.
Pageof 17